



Olumiant in India

The CDSCO named-patient coordination pathway — indicative 2026

IMMUNOLOGY · JAK1/JAK2 INHIBITOR

The clinical situation

Olumiant (baricitinib) is an FDA-approved oral selective JAK1/JAK2 inhibitor indicated for moderate-to-severe rheumatoid arthritis, severe alopecia areata, and juvenile idiopathic arthritis. Manufactured by Lilly (Incyte). Standard dosing is 2 mg or 4 mg once daily by indication; ambient-storage oral tablet with renal dose adjustment and the class boxed warning for serious infections, malignancy, MACE, thrombosis, and mortality.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your treating rheumatologist or dermatologist documents diagnosis, prior biologic/JAK exposure, TB/HBV/HCV/herpes-zoster screening, and eligibility.
- 2 Treating centre confirmed.** An Indian tertiary rheumatology or dermatology centre in Mumbai, Delhi, Bengaluru, or Chennai accepts the case.
- 3 CDSCO named-patient application.** Clinical rationale, patient reference, and product details are filed under CDSCO's personal-import pathway; Form-10/Form-12 as applicable.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner; ambient-temperature shipment.
- 5 Arrival & administration.** Patient begins once-daily dosing under physician monitoring; disease activity, CBC, LFTs, and lipids rechecked per label.

Indicative economics

Reference US cash-pay range: USD 2,400–2,800 per 30-day supply. CDSCO documentation, logistics, and concierge coordination are incremental. Full transparent quote at intake.

Indicative first-dose timing

7–14 days from a complete CDSCO application to first-dose delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and CDSCO review. **Logistics.** Ambient-temperature shipment coordination. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating specialist.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Olumiant × India first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/olumiant-india.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team